Catalent joins the EuropaBio 25th Anniversary in 2021
Brussels, Belgium – March 9 2021 – EuropaBio today announced that Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, has joined EuropaBio’s 25th Anniversary Celebration Programme as a major sponsor.
With a mission to celebrate the most significant scientific and commercial advances in European biotechnology over the last 25 years, Europe’s leading life sciences industry association commenced its quarter century anniversary celebrations in March with the launch of a dedicated website at www.europabio25.org.
During 2021, EuropaBio, together with its members and partners, will nominate the most impactful cross-sector developments from the last 25 years and showcase how they have benefitted society and the environment. The commemoration of 25 years of scientific advances will be amplified through webinars, interviews, and reviews discussing some of the key drivers of biotechnology innovation. The year’s programme of celebratory events will end in December with a gala evening in Brussels and the presenting of the 2021 SME Award from EuropaBio.
In joining the EuropaBio programme, Catalent will bring its expertise and global biotechnology capabilities to the celebrations. Dr Claire Skentelbery, Director General of EuropaBio commented, “We are absolutely delighted to welcome the Catalent team to our 25th anniversary celebrations. They share our passion for biotech as a solution for people and planet and will help shine a light on the advances in the science that enables solutions to be delivered.”
“Europe is an important centre of innovation, and Catalent’s recent expansions to add cell therapy and plasmid DNA capabilities in Belgium, and significant biologics manufacturing capacity in Italy means that we are well placed to help accelerate the development and availability of biotechnologies to help people live longer, healthier lives,” commented Julien Meissonnier, Vice President and Chief Scientific Officer, Catalent. “As we celebrate the significant advances in biotechnology during EuropaBio’s 25th anniversary year, the pandemic reminds us of the importance of collaboration, continued innovation, and technological advancement in this important field.”
Join in the EuropaBio anniversary celebrations for the whole of 2021 through our newsletter and visit the dedicated Anniversary website at www.europabio25.org.
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 15,000 people, including approximately 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com